VANTAGE BIOSCIENCES LTD

Active London

Research and experimental development on biotechnology

2 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
V

VANTAGE BIOSCIENCES LTD

Research and experimental development on biotechnology

Founded 10 Mar 2023 Active London, England 2 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 31 Mar 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 18 Mar 2026 Next due 21 Mar 2027 11 months remaining
Net assets £5M £3M 2024 year on year
Total assets £7M £5M 2024 year on year
Total Liabilities £2M £2M 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

78 Pall Mall London SW1Y 5ES England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for VANTAGE BIOSCIENCES LTD (14721262), an active life sciences and medical technology company based in London, England. Incorporated 10 Mar 2023. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

N/A

Net Assets

£4.73M

Increased by £3.17M (+203%)

Total Liabilities

£2.13M

Increased by £2.01M (+1705%)

Turnover

N/A

Employees

2

Debt Ratio

31%

Increased by 24 (+343%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1

Investors (1)

Investor NameInvestor SinceParticipating Rounds
Investor 1Jul 2023Seed

Share Capital

Share Capital

Share allotments and capital structure

5 Allotments 10,199,000 Shares £3997988.01m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
25 Mar 2025100,000£1k£1k
25 Mar 20254,000,000£4.00m£4.00m
2 Sept 20244,000,000£4.00m£4.00m
2 Sept 2024100,000£1k£1k
12 Apr 20231,999,000£3997980.01m£2.00m

Officers

Officers

2 active
Status
Martin, Graeme Richard, DrDirectorBritishEngland7127 Mar 2023Active
Safarian, AlekDirectorAustralianUnited States6110 Mar 2023Active

Shareholders

Shareholders (2)

Alsa Ventures I Scsp
97.6%
10,000,000
Katie Ghani
2.4%
250,000

Persons with Significant Control

Persons with Significant Control (2)

2 Active

Mr Alek Safarian

Australian

Active
Notified 10 Mar 2023
Residence United States
DOB October 1964
Nature of Control
  • Ownership Of Shares 75 To 100 Percent
  • Voting Rights 75 To 100 Percent
  • Right To Appoint And Remove Directors

Alsa Ventures I Scsp

Luxembourg

Active
Notified 11 Apr 2023
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent

Group Structure

Group Structure

VANTAGE BIOSCIENCES LTD Current Company

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
18 Mar 2026Confirmation StatementConfirmation statement made on 2026-03-07 with updates
9 Mar 2026MortgageMortgage Satisfy Charge Full
24 Sept 2025CapitalAllotment of shares (GBP 61,500) on 2025-03-25
16 Jun 2025Persons With Significant ControlChange to Mr Alek Safarian as a person with significant control on 2025-04-06
16 Jun 2025OfficersChange to director Mr Alek Safarian on 2025-04-06
18 Mar 2026 Confirmation Statement

Confirmation statement made on 2026-03-07 with updates

9 Mar 2026 Mortgage

Mortgage Satisfy Charge Full

24 Sept 2025 Capital

Allotment of shares (GBP 61,500) on 2025-03-25

16 Jun 2025 Persons With Significant Control

Change to Mr Alek Safarian as a person with significant control on 2025-04-06

16 Jun 2025 Officers

Change to director Mr Alek Safarian on 2025-04-06

Recent Activity

Latest Activity

Confirmation statement made on 2026-03-07 with updates

1 months ago on 18 Mar 2026

Mortgage Satisfy Charge Full

1 months ago on 9 Mar 2026

Allotment of shares (GBP 61,500) on 2025-03-25

6 months ago on 24 Sept 2025

Change to Mr Alek Safarian as a person with significant control on 2025-04-06

10 months ago on 16 Jun 2025

Change to director Mr Alek Safarian on 2025-04-06

10 months ago on 16 Jun 2025